Search
Now showing items 1-5 of 5
Immune and muli-omic profiling for molecular classification and biomarker discovery in soft tissue sarcoma
(Institute of Cancer Research (University Of London), 2020-02-29)
Soft tissue sarcomas (STS) are a group of over 50 rare cancers of mesenchymal origin. Classification of STS is primarily based on histological characteristics of tumours. Novel biomarkers are required that account for the ...
Telemedicine During the COVID-19 Pandemic: Impact on Care for Rare Cancers.
(AMER SOC CLINICAL ONCOLOGY, 2020-06-01)
PURPOSE: Many patients with cancer, often those with rare cancers such as sarcomas, travel long distances to access expert care. The COVID-19 pandemic necessitated widespread changes in delivery of cancer care, including ...
Adult soft tissue myoepithelial carcinoma: treatment outcomes and efficacy of chemotherapy.
(OXFORD UNIV PRESS, 2019-12-27)
Soft tissue myoepithelial carcinomas are a rare, malignant subgroup of myoepithelial tumours mostly arising in the extremities with equal predilection for women and men. The mainstay of management of localised disease is ...
The adequacy of tissue microarrays in the assessment of inter- and intra-tumoural heterogeneity of infiltrating lymphocyte burden in leiomyosarcoma.
(NATURE PORTFOLIO, 2019-10-10)
The characterisation and clinical relevance of tumour-infiltrating lymphocytes (TILs) in leiomyosarcoma (LMS), a subtype of soft tissue sarcoma that exhibits histological heterogeneity, is not established. The use of tissue ...
OX40 and 4-1BB delineate distinct immune profiles in sarcoma.
(TAYLOR & FRANCIS INC, 2022-12-31)
Systemic relapse after radiotherapy and surgery is the major cause of disease-related mortality in sarcoma patients. Combining radiotherapy and immunotherapy is under investigation as a means to improve response rates. ...